Skip to content

Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023
13.66 -0.50 -3.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 14.10 -0.42%
After-hours 13.70 +0.29%
Overnight 13.88 -1.98%
31.5413.6613.662026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MLYS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -57.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -36.9% Better than 11%
Return on invested capital -40.7% Better than 7%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -46.7% Better than 7%
6-month return -54.2% Better than 6%
12-month return (ex latest month) -50.9% Better than 3%
Distance below 52-week high 69.0% Better than 6%
Financial Health D+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 43.8x Better than 100%
Debt to assets 302.8% Better than 0%
Interest coverage -717.8x Better than 2%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 233.1% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.89%
1M -36.70%
3M -46.95%
6M -51.95%
YTD -62.36%
1Y -67.38%
3Y +112.44%

Key statistics

Price & volume

Prev close
14.16
Open
13.81
Day range
13.57 - 14.79
Avg price
13.86
Volume
1.35M
Turnover
18.65M
Amplitude
8.62%
52-week range
13.57 - 44.13

Valuation

P/E
-5.97
P/E (TTM)
-3.18
P/B
2.40
EPS
-2.29
Net profit
-202.80M
Net assets
503.80M

Share structure

Market cap
1.21B
Float cap
911.75M
Shares out
88.56M
Float shares
66.75M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2023-02-10
52-week range 0% of range
13.57 44.13

69.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-10.90M net over the window

Short interest

Shares short
7.69M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Mineralys Therapeutics (MLYS)?

Mineralys Therapeutics last traded at 13.66. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Mineralys Therapeutics's market cap?

About 1.21B.

What is the P/E ratio of Mineralys Therapeutics?

The trailing twelve-month P/E is -3.18. The Valuation tab shows it against the stock's own five-year range.

Does Mineralys Therapeutics pay a dividend?

Mineralys Therapeutics does not currently pay a regular dividend.

Is Mineralys Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 45.50, which implies 233.1% upside from the current price. This is not investment advice.

What is Mineralys Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Mineralys Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mineralys Therapeutics discussion 0 comments

Add a comment